Fingolimod

Fingolimod is a sphingosine-1-phosphate (S1P) receptor modulator, an immunomodulating drug used as a disease-modifying therapy for multiple sclerosis ^[1]. It was derived from myriocin, a compound obtained from the fungus Isaria sinclairii, and was developed by Novartis under the brand name Gilenya. Its approval by the United States Food and Drug Administration in 2010 was a milestone, as it became the first oral disease-modifying treatment for multiple sclerosis at a time when the available therapies required injection ^[1].

It is used for relapsing forms of multiple sclerosis, in which periods of neurological worsening alternate with recovery ^[1]. In the pivotal FREEDOMS trial, fingolimod significantly reduced the annual relapse rate and slowed disability progression compared with placebo, while also improving findings on magnetic resonance imaging ^[2]. In the TRANSFORMS trial it lowered relapse rates more than an established injectable interferon beta therapy ^[3]. Its efficacy in primary progressive multiple sclerosis, a steadily worsening form without relapses, has not been demonstrated ^[1].

The drug is taken as a daily oral capsule and is used with care because it carries distinctive risks ^[1]. Because it affects S1P receptors on heart tissue, the first dose can slow the heart rate, so patients are monitored when starting treatment; other recognized effects include swelling at the back of the eye (macular edema), raised liver enzymes, high blood pressure and a greater susceptibility to certain infections ^[2]. Its use is avoided in pregnancy ^[1].

Fingolimod is a prescription-only medicine, and generic versions became available in the years after its patents lapsed ^[1].

Fingolimod is a well-characterized prescription drug, but it carries real, monitorable risks and is not something to use casually. The best-known one is a first-dose heart-rate slowdown; the first dose is normally taken under cardiac monitoring, and it is cautioned in people with heart-rhythm issues or on heart-rate-lowering drugs. Because it works by trapping lymphocytes, it lowers your circulating immune cells and raises infection risk, including rare serious ones, so live vaccines are discouraged while on it.

Other labeled watch-items include macular edema (eye checks are recommended), liver-enzyme elevation (bloodwork), lymphopenia (expected and monitored), raised blood pressure, and fetal risk in pregnancy. It has a long half-life, on the order of days, so it lingers for weeks after stopping, and abruptly stopping can occasionally trigger a severe MS rebound. Bottom line: this is a prescription immunotherapy taken under medical supervision with baseline testing and first-dose monitoring, not a research chemical for self-experimentation.

Ketoconazole inhibits CYP4F2, the enzyme responsible for fingolimod hydroxylation and inactivation, resulting in increased fingolimod and fingolimod-phosphate exposure ^[4]. Ketoconazole increased fingolimod AUC over five days by 1.40-fold and total AUC to infinity by 1.71-fold in a human study. This is a pharmacokinetic interaction. Active metabolite fingolimod-phosphate was similarly increased 1.67-fold. Clinicians managing fingolimod should be aware of this interaction and consider clinical monitoring or dose reduction, though routine adjustment may not be necessary for mild-to-moderate ketoconazole exposure. No documented interactions with other multiple sclerosis therapies or commonly coadministered agents have been published; the risk profile with concurrent immunosuppressants remains understudied.

Checking a whole stack? Run it through interactions + stacks.